While the overall Indian pharmaceutical market is seeing early signs of a rebound after a dull 2013, interest is steadily building for buyout targets like high yield brands, medical devices and companies that bring expertise to manufacturing.

While the overall Indian pharmaceutical market is seeing early signs of a rebound after a dull 2013, interest is steadily building for buyout targets like high yield brands, medical devices and companies that bring expertise to manufacturing.

The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.